SCHEMBL2811777

SCHEMBL2811777

C/C(=C\Oc1ccccc1)C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.49
RAB9A P51151 6/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
NPC1 O15118 5/20 0.47
MAPT P10636 6/20 0.46
KMT2A Q03164 6/20 0.46
MEN1 O00255 5/20 0.46
GAA P10253 2/20 0.46
RECQL P46063 1/20 0.46
GFER P55789 1/20 0.46
HTT P42858 3/20 0.45
ALDH1A1 P00352 4/20 0.45
EGFR P00533 1/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
LMNA P02545 2/20 0.43
ALOX12 P18054 1/20 0.43
G6PD P11413 1/20 0.43
CACNA1B Q00975 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2811781 1.00 CYP19A1 (0.49) CYP19A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL2808886 0.94 MEN1 (0.46) CYP19A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL2808882 0.94 MEN1 (0.46) CYP19A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL2811479 0.90 NAPRT (0.48) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL2811474 0.90 NAPRT (0.48) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL2807384 0.87 ALDH1A1 (0.50) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL2807379 0.87 ALDH1A1 (0.50) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL2812461 0.86 RAB9A (0.54) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL2812456 0.86 RAB9A (0.54) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL2808956 0.86 MAPT (0.49) RAB9ASMN1; SMN2NPC1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278473-B2 Alpha, beta-unsaturated imidate compound and pesticidal composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-02 US disclosed
US-8278473-B2 Alpha, beta-unsaturated imidate compound and pesticidal composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-02 US disclosed
US-8278473-B2 Alpha, beta-unsaturated imidate compound and pesticidal composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-02 US disclosed
US-20100240729-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-23 US disclosed
US-20100240729-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-23 US disclosed
US-20100240729-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-23 US disclosed
WO-2009064031-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-05-22 WO disclosed
WO-2009064031-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240729-A1 ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME OXER1, CBR1, DEGS1 CYP19A1 184/4885RAB9A 1842/4885SMN1; SMN2 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.